These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17523751)

  • 21. The decision rules of cost-effectiveness analysis.
    Karlsson G; Johannesson M
    Pharmacoeconomics; 1996 Feb; 9(2):113-20. PubMed ID: 10160090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance.
    Obenchain RL; Robinson RL; Swindle RW
    J Biopharm Stat; 2005; 15(3):419-36. PubMed ID: 15920889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A note on confidence intervals in cost-effectiveness analysis.
    Tambour M; Zethraeus N; Johannesson M
    Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored.
    Blackhouse G; Briggs AH; O'Brien BJ
    Med Decis Making; 2002; 22(2):173-7. PubMed ID: 11958499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Problems with interval estimates of the incremental cost-effectiveness ratio.
    Heitjan DF; Moskowitz AJ; Whang W
    Med Decis Making; 1999; 19(1):9-15. PubMed ID: 9917015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonparametric statistical methods for cost-effectiveness analyses.
    Dinh P; Zhou XH
    Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.
    Chaudhary MA; Stearns SC
    Stat Med; 1996 Jul; 15(13):1447-58. PubMed ID: 8841654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [From the therapeutic utility to the added therapeutic value and the incremental cost-effectiveness ratio].
    Puig-Junoy J; Peiró S
    Rev Esp Salud Publica; 2009; 83(1):59-70. PubMed ID: 19495489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease.
    Sørensen SS; Pedersen KM; Weinreich UM; Ehlers L
    Appl Health Econ Health Policy; 2017 Jun; 15(3):413-424. PubMed ID: 27928660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes.
    Briggs AH
    Int J Technol Assess Health Care; 2001; 17(1):69-82. PubMed ID: 11329846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
    Araki D; Kamae I
    Kobe J Med Sci; 2015 Mar; 61(1):E9-18. PubMed ID: 25868612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size determination for cost-effectiveness trials.
    Willan AR
    Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.
    Backhouse ME
    Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.
    O'Brien BJ; Drummond MF; Labelle RJ; Willan A
    Med Care; 1994 Feb; 32(2):150-63. PubMed ID: 8302107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals.
    Severens JL; De Boo TM; Konst EM
    Int J Technol Assess Health Care; 1999; 15(3):608-14. PubMed ID: 10874387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.
    Hoyle M; Anderson R
    Med Decis Making; 2010; 30(4):426-37. PubMed ID: 20228287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fieller's method and net health benefits.
    Heitjan DF
    Health Econ; 2000 Jun; 9(4):327-35. PubMed ID: 10862076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
    Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
    BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.